Question · Q3 2025
Tazim Ahmed asked about the upcoming mCALR data, specifically the importance of the monotherapy arm for demonstrating efficacy as a standalone treatment, and what level of efficacy would be convincing, even in combination with Jakafi.
Answer
President Pablo Cagnoni emphasized 989 as the first targeted therapy for MPNs, highlighting the need to demonstrate single-agent activity with clinical endpoints (spleen reduction, symptom improvement, anemia) and translational endpoints. He referenced momelotinib (SVR35 7-22%, TSS50 25-26%) as a benchmark for previously treated patients. CEO Bill Meury reinforced the importance of the question.